| oxaliplatin / Generic mfg. |
| Completed | 2b | 198 | US, Europe, RoW | Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin), Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin) | Bayer, Amgen | Metastatic Colorectal Cancer | 01/11 | 02/12 | | |
|
NCT00004127: Oxaliplatin Combined With Fluorouracil and Leucovorin in Treating Patients With Recurrent or Metastatic Cancer of the Esophagus or Stomach |
|
|
| Completed | 2 | 35 | US | FOLFOX regimen, fluorouracil, leucovorin calcium, oxaliplatin | University of Chicago, National Cancer Institute (NCI) | Esophageal Cancer, Gastric Cancer | 10/02 | 08/03 | | |
NCT00065117: Safety, Tolerability and Efficacy of ZD6126 in Combination With Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects With Metastatic Colorectal Cancer. |
|
|
| Terminated | 2 | 180 | US | ZD6126, Placebo, 5-fluorouracil, leucovorin, oxaliplatin | AstraZeneca | Colorectal Neoplasms, Metastases, Neoplasm | 02/04 | 02/04 | | |
NCT00070265: Neoadjuvant and Adjuvant Capecitabine and Oxaliplatin in Treating Patients With Resectable Liver Metastases Secondary to Colorectal Cancer |
|
|
| Terminated | 2 | 80 | US | oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, capecitabine, CAPE, Ro 09-1978/000, Xeloda, therapeutic conventional surgery, laboratory biomarker analysis | National Cancer Institute (NCI) | Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer | 09/04 | | | |
NCT00003834: Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer |
|
|
| Completed | 2 | 44 | US, Canada | fluorouracil, leucovorin calcium, oxaliplatin | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Colorectal Cancer, Metastatic Cancer | 12/05 | 12/05 | | |
NCT00026234: Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver |
|
|
| Completed | 2 | 75 | US | floxuridine, 5-FUDR, dexamethasone, Aeroseb-Dex, Decaderm, Decadron, DM, DXM, oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, capecitabine, CAPE, Ro 09-1978/000, Xeloda | National Cancer Institute (NCI), NSABP Foundation Inc | Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer | 01/06 | | | |
NCT00120172: Study of Oxaliplatin, Capecitabine, and Bevacizumab to Treat Older Patients With Colorectal Cancer |
|
|
| Terminated | 2 | 40 | US | oxaliplatin, capecitabine, bevacizumab | Geriatric Oncology Consortium, Sanofi | Colorectal Cancer, Neoplasm Metastasis | | 06/06 | | |
NCT00103298: Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer |
|
|
| Completed | 2 | | US | FOLFOX regimen, fluorouracil, isolated perfusion, leucovorin calcium, melphalan, oxaliplatin | National Cancer Institute (NCI) | Colorectal Cancer, Metastatic Cancer | | 07/06 | | |
NCT00123851: Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 32 | US | Tarceva (OSI-774), Capecitabine, Oxaliplatin | Dana-Farber Cancer Institute, Sanofi-Synthelabo, OSI Pharmaceuticals, Hoffmann-La Roche, Genentech, Inc., Massachusetts General Hospital, Beth Israel Deaconess Medical Center | Colorectal Cancer, Neoplasm Metastasis | 08/06 | 08/06 | | |
NCT00353145: Gemox as First and Second Line Therapy in Unknown Primary Cancer |
|
|
| Completed | 2 | 29 | US | Gemcitabine (Gemox), Gemcitabine Hydrochloride, Gemzar, Oxaliplatin, Eloxatin, Questionnaire | M.D. Anderson Cancer Center, Sanofi-Synthelabo | Unknown Primary Neoplasms | 03/07 | 01/10 | | |
OPUS, NCT00125034: Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC) |
|
|
| Completed | 2 | 344 | Europe, RoW | Cetuximab, Oxaliplatin | Merck KGaA, Darmstadt, Germany | Neoplasm Metastasis, Colorectal Cancer | 03/07 | 11/10 | | |
|
|
|
|
|
NCT00118105: S0408: Capecitabine, Oxaliplatin, and Bevacizumab in Pts Undergoing Surgery for Liver Mets From Colorectal Cancer |
|
|
| Withdrawn | 2 | 0 | US | bevacizumab, Avastin, NSC-704865, capecitabine, Xeloda, NSC-712807, oxaliplatin, NSC-266046, conventional surgery | Southwest Oncology Group, National Cancer Institute (NCI), Eastern Cooperative Oncology Group | Colorectal Cancer, Metastatic Cancer | 04/07 | 04/07 | | |
NCT00083616: Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy |
|
|
| Completed | 2 | 185 | US | Panitumumab, ABX-EGF, Vectibix | Amgen | Colorectal Cancer, Metastatic Cancer | 05/07 | 12/08 | | |
NCT00346099: Study of Panitumumab Given First With Capecitabine and Oxaliplatin (CAPOX) and Then With Capecitabine and Radiation of the Pelvis for Treatment of Patients With Rectal Cancers That May or May Not Have Spread Beyond the Rectum |
|
|
| Withdrawn | 2 | 0 | US | Panitumumab with capecitabine and oxaliplatin (CAPOX) followed by, Panitumumab with capecitabine and radiation | NSABP Foundation Inc, Amgen | Rectal Cancer, Neoplasm Metastasis | | 05/07 | | |
NCT00043004: Chemotherapy and Bevacizumab With or Without Radiofrequency Ablation in Treating Unresectable Liver Metastases in Patients With Colorectal Cancer |
|
|
| Terminated | 2 | 119 | Europe, RoW | bevacizumab, FOLFOX regimen, fluorouracil, leucovorin calcium, oxaliplatin, conventional surgery, radiofrequency ablation | European Organisation for Research and Treatment of Cancer - EORTC, Arbeitsgruppe Lebermetastasen und Tumoren, Institute of Cancer Research, United Kingdom | Colorectal Cancer, Metastatic Cancer | 06/07 | | | |
NCT00056030: Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer |
|
|
| Completed | 2 | 73 | US | cetuximab, fluorouracil, leucovorin calcium, oxaliplatin | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Colorectal Cancer, Metastatic Cancer | 10/07 | | | |
NCT00305786: Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer |
|
|
| Completed | 2 | 30 | US | gemcitabine hydrochloride, oxaliplatin | University of Miami | Lung Cancer | 12/07 | 05/10 | | |
NCT00153998: Cetuximab in Neoadjuvant Treatment of Non-Resectable Colorectal Liver Metastases (CELIM) |
|
|
| Completed | 2 | 135 | Europe | Cetuximab, Liver resection, Cetuximab and FOLFIRI, Cetuximab(C225, Erbitux®, Merck KGaA), Irinotecan (irinotecan HCl, CPT-11 or Campto®, Aventis), 5-Fluorouracil (5-FU), Folinic acid (FA, i.e. Leucovorin®, Wyeth), Cetuximab and FOLFOX, Oxaliplatin (L-OHP, Eloxatin®, Sanofi-Synthelabo) | Technische Universität Dresden | Colorectal Cancer, Liver Metastases | 03/08 | | | |
|
|
|
|
NCT00193609: Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site |
|
|
| Completed | 2 | 48 | US | Oxaliplatin, Eloxatin, Capecitabine, Xeloda | SCRI Development Innovations, LLC, Roche Pharma AG, Sanofi-Synthelabo | Neoplasms, Unknown Primary | 04/08 | 01/09 | | |
NCT00408772: Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer |
|
|
| Withdrawn | 2 | 0 | US | bevacizumab, capecitabine, oxaliplatin, conventional surgery, neoadjuvant therapy, radiofrequency ablation | University of California, Davis, Sanofi | Colorectal Cancer, Metastatic Cancer | 04/08 | 04/08 | | |
NCT00508872: Folfox-B Study for Patients With Colorectal Liver Metastases |
|
|
| Terminated | 2 | 2 | US | 5-Fluorouracil, 5-FU, Adrucil, Efudex, Bevacizumab, Avastin, Anti-VEGF monoclonal antibody, rhuMAb-VEGF, Leucovorin, Citrovorum, Wellcovorin, Oxaliplatin, Eloxatin | M.D. Anderson Cancer Center, Sanofi | Colorectal Liver Metastases | 06/09 | 06/09 | | |
TIROX2, NCT00512681: A Phase II Study of Irinotecan, Oxaliplatin, Plus TS-1 in Untreated Metastatic Gastric Cancer |
|
|
| Completed | 2 | 44 | RoW | Irinotecan, Oxaliplatin, TS-1 | National Cancer Center, Korea | Stomach Neoplasms | 07/09 | 07/09 | | |
NCT00557206: Oxaliplatin and Docetaxel for Recurrent or Metastatic Head and Neck Cancer |
|
|
| Terminated | 2 | 35 | US | Oxaliplatin and Docetaxel | Minneapolis Veterans Affairs Medical Center, Sanofi | Neoplasms, Head and Neck Neoplasms | 11/09 | 11/09 | | |
NCT00537823: Pre- and Post-operative FOLFOX Based Therapy for Patients With Colorectal Cancer With Liver Involvement |
|
|
| Terminated | 2 | 9 | US | Cetuximab, Erbitux, Bevacizumab, Avastin, Leucovorin, Oxaliplatin, Fluorouracil | Washington University School of Medicine | Colorectal Cancer, Metastases | 12/09 | 07/11 | | |
NCT01022541 / 2005-004505-29: Capecitabine and Oxaliplatin Plus Bevacizumab as Neoadjuvant Treatment for Untreated Unresectable Liver-only Metastases From Colorectal Cancer |
|
|
| Completed | 2 | 47 | Europe | Capecitabine, Xeloda, Oxaliplatin, Eloxatin, Bevacizumab, Avastin, Liver metastasectomy | Royal Marsden NHS Foundation Trust, Roche Pharma AG | Metastatic Colorectal Cancer | 12/10 | 02/15 | | |
|
|
HEARTO, NCT01348412: Hepatic Arterial Chemotherapy With Raltitrexed and Oxaliplatin Versus Standard Chemotherapy in Unresectable Liver Metastases From Colorectal Cancer After Conventional Chemotherapy Failure |
|
|
| Completed | 2 | 31 | Europe | oxaliplatin, raltitrexed, other intravenous chemotherapy drugs | Centre Georges Francois Leclerc, National Cancer Institute, France, Hospira, now a wholly owned subsidiary of Pfizer | Colorectal Cancer, Liver Metastases | 12/10 | 04/18 | | |
APRIORI, NCT01126866: Curative Resectability of Not Optimally Resectable Liver and/or Lung Metastases From Colorectal Carcinoma (CRC) Under Intensified Chemotherapy |
|
|
| Terminated | 2 | 35 | Europe | intensified chemotherapy (FOLFOXIRI/Bevacizumab) | National Center for Tumor Diseases, Heidelberg, Roche Pharma AG, Pfizer | Colorectal Carcinoma | 03/11 | 06/11 | | |
| Completed | 2 | 268 | Europe, RoW | aflibercept, ZALTRAP™, AVE0005, oxaliplatin, 5-FU, Folinic Acid | Sanofi | Colorectal Neoplasms, Neoplasm Metastasis | 04/11 | 01/12 | | |
|
NCT00544349: Leucovorin, Fluorouracil, Cetuximab, and Oxaliplatin in Treating Patients With Stage IV Colorectal Cancer and Liver Metastases That Cannot Be Removed by Surgery |
|
|
| Completed | 2 | 45 | Europe | cetuximab, fluorouracil, leucovorin calcium, oxaliplatin | Gustave Roussy, Cancer Campus, Grand Paris | Colorectal Cancer, Metastatic Cancer | 05/11 | | | |
|
NCT00700570: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 45 | RoW | bevacizumab [Avastin], capecitabine [Xeloda], oxaliplatin | Hoffmann-La Roche | Colorectal Cancer | 11/11 | 11/11 | | |
NCT00743678: Neoadjuvant FOLFOX6 + Cetuximab in Patients With Colorectal Cancer and Unresectable Liver Metastasis |
|
|
| Completed | 2 | 73 | RoW | FOLFOX6/cetuximab | Samsung Medical Center | Colorectal Cancer, Unresectable Liver Metastasis | 01/12 | 06/12 | | |
| Withdrawn | 2 | 0 | Canada | irinotecan, capecitabine, oxaliplatin (IXO) and bevacizumab | Ottawa Hospital Research Institute, Hoffmann-La Roche, Sanofi | Metastatic Colorectal Cancer | 02/12 | 02/12 | | |
| Completed | 2 | 171 | US, Europe, RoW | CT-011, FOLFOX | Medivation, Inc. | Metastatic Colorectal Cancer | 05/12 | 03/13 | | |
|
NCT01157039: A Trial of Glutamine to Prevent Oxaliplatin Neurotoxicity and a Pharmacokinetic Analysis of Oxaliplatin |
|
|
| Withdrawn | 2 | 0 | Canada | Glutamine, L-glutamine | AHS Cancer Control Alberta, Cross Cancer Institute | Colorectal Carcinoma, Neoplasms, Colorectal, Colorectal Cancer, Colorectal Tumors, Metastasis | 09/12 | | | |
NCT01703910 / 2012-001307-20: Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic |
|
|
| Completed | 2 | 29 | Europe | Arm A chemotherapy, Capecitabine, Cisplatin, Cetuximab, Doxorubicin, Fluorouracil, Gemcitabine, Irinotecan, Topotecan, Mitomycin C, Oxaliplatin, Paclitaxel, Docetaxel, Pemetrexed, Raltitrexed, Sorafenib, Erlotinib, Vinorelbine, Dasatinib, Etoposide, arm B chemotherapy | Centro Nacional de Investigaciones Oncologicas CARLOS III, Hospital Universitario de Fuenlabrada, Grupo Hospital de Madrid, Apices Soluciones S.L. | Adenocarcinoma of Colon, Adenocarcinoma of Rectum, Metastatic Disease | 11/12 | 12/14 | | |
NCT02071043: Trial of Xeloda and Oxaliplatin (XELOX) as Neo-adjuvant Chemotherapy Followed by Surgery in Advanced Gastric Cancer Patients With Para-aortic Lymph Node Metastasis |
|
|
| Completed | 2 | 48 | RoW | Capecitabine, Oxaliplatin | Shanghai Zhongshan Hospital | Advanced Gastric Cancer | 01/13 | 01/13 | | |
| Withdrawn | 2 | 0 | Europe | Bevacizumab, VEGF antibody | University of Regensburg, University of Halle Medical Faculty | Colon Cancer Liver Metastasis | 05/13 | 05/13 | | |
| Completed | 2 | 80 | Europe | 5-FU, Irinotecan, Leucovorin, Oxaliplatin, bevacizumab [Avastin] | Hoffmann-La Roche | Colorectal Cancer | 10/13 | 10/13 | | |
|
| Completed | 2 | 45 | Europe | Trastuzumab, Herceptin, Capecitabine, Xeloda, Oxaliplatin, Oxaliplatino | Fundación para el Progreso de la Oncología en Cantabria | Stage IV Gastric Cancer With Metastasis | 12/13 | 05/15 | | |
NCT02345746: Hepatic Arterial Infusion With FOLFOX Alone or in Combination With IV Chemotherapy in Colon Cancer With Liver Metastasis |
|
|
| Withdrawn | 2 | 0 | NA | Oxaliplatin, Eloxatin®, Folinic Acid, Leucovorin, 5-Fluorouracil, 5-FU | Western Regional Medical Center | Metastatic Colorectal Cancer | 12/13 | 12/13 | | |
| Completed | 2 | 60 | US | capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin) | Duke University, Hoffmann-La Roche, Sanofi, Genentech, Inc. | Esophageal Neoplasms, Stomach Neoplasms, Neoplasm Metastasis | 01/14 | 07/14 | | |
|
NCT01226719: FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only |
|
|
| Completed | 2 | 15 | US | Panitumumab, Combined Modality Treatment, Oxaliplatin, Irinotecan, Leucovorin, 5-Fluorouracil | SCRI Development Innovations, LLC, Amgen | Colorectal Cancer | 03/14 | 03/14 | | |
|
| Completed | 2 | 77 | Europe | 5-Fluorouracil (5-FU), Bevacizumab, Avastin, Levofolinic acid, Oxaliplatin | Hoffmann-La Roche | Colorectal Cancer | 05/14 | 05/16 | | |
PRIMM, NCT01715363: Feasibility of an Immediate Preoperative Chemotherapy Before Resection fo Colorectal Cancer |
|
|
| Terminated | 2 | 3 | Europe | Oxaliplatin, Folinic Acid, Fluorouracile | Gustave Roussy, Cancer Campus, Grand Paris | Patients With Colorectal Cancer With Unresectable Synchronous Metastasis in Whom Resection of the Primitive Tumour is Indicated | 06/14 | 06/14 | | |
NCT01937507: Hepatic Artery Infusion With FOLFOX in Liver Metastasis From Breast Cancer |
|
|
| Terminated | 2 | 2 | US | HAI with FOLFOX, Hepatic Artery Infusion | Western Regional Medical Center | Metastatic Breast Cancer | 07/14 | 07/14 | | |
NCT01320683: Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer |
|
|
| Terminated | 2 | 1 | US | oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, leucovorin calcium, CF, CFR, LV, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, bevacizumab, anti-VEGF humanized monoclonal antibody, anti-VEGF monoclonal antibody, Avastin, rhuMAb VEGF, yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A, laboratory biomarker analysis, pharmacological study, pharmacological studies, irinotecan hydrochloride, Campto, Camptosar, CPT-11, irinotecan, U-101440E | City of Hope Medical Center, National Cancer Institute (NCI) | Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer | 12/14 | 12/14 | | |
| Completed | 2 | 80 | Europe | Panitumumab+FOLFOX-4, Panitumumab+FOLFIRI | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Amgen | Colorectal Cancer | 03/15 | 03/15 | | |
|
|
|
|
NCT01269229: A Trial of Neoadjuvant FOLFOX6 With Short Course Radiotherapy in Patients With Unresectable Rectal Cancer and Liver Metastasis |
|
|
| Completed | 2 | 32 | RoW | folfox, short course Radiotherapy | Yonsei University | Rectal Cancer | 04/15 | 04/15 | | |
NCT01858662 / 2012-005249-19: Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors |
|
|
| Terminated | 2 | 4 | Europe | Metastases Resection ( multiple steep surgery possible), 5-Fluorouracile, 5FU, leucovorin L, elvorine, isovorin, Oxaliplatin, Eloxatin, Irinotecan, Campto, Irinosin, Cetuximab, erbitux | Cliniques universitaires Saint-Luc- Université Catholique de Louvain, Grand Hôpital de Charleroi | Metastatic Colorectal Cancer | 11/15 | 11/15 | | |
NCT01581307: Phase II Trial Evaluating OS With Therasphere® + 2nd-Line FOLFOX in Pancreatic Liver Mets |
|
|
| Completed | 2 | 9 | US | FOLFOX7 (Folinic acid, 5-Fluorouracil, and Oxaliplatin), Leucovorin, LV, FOL, OX, 5-Fluorouracil (5-FU), FOLFOX, ELOXATIN, TheraSpheres, radiotherapy, radioembolization | H. Lee Moffitt Cancer Center and Research Institute, BTG International Inc. | Liver Cancer, Pancreatic Cancer | 02/16 | 03/16 | | |
| Completed | 2 | 10 | Europe | Bevacizumab, Capecitabine, Irinotecan | Gustave Roussy, Cancer Campus, Grand Paris | Colorectal Neoplasms | 02/16 | 02/16 | | |
|
PREVIUM, NCT02175654 / 2014-000703-26: Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab |
|
|
| Terminated | 2 | 15 | Europe | Regorafenib | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Bayer | Colorectal Neoplasms, Metastatic Disease | 02/16 | 02/16 | | |
| Terminated | 2 | 44 | Europe | FOLFOX6, Chemotherapy, Bevacizumab, Avastin, Panitumumab, Vectibix, Surgery | European Organisation for Research and Treatment of Cancer - EORTC, Amgen, Roche Pharma AG | Colorectal Cancer Metastatic, Liver Metastases, KRAS Wild Type Colorectal Cancer | 09/16 | 09/16 | | |
|
ATOM, NCT01836653: Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases |
|
|
| Completed | 2 | 122 | Japan | Bevacizumab, Avastin, Cetuximab, Erbitux, L-OHP, Oxaliplatin, l-LV, Levofolinate, 5-FU, Fluorouracil | EPS Corporation | Liver Only Metastasis From KRAS Exon 2 Wild Type (Under Protocol 1.0-1.2 Edition) and RAS Wild Type (Under Protocol 2.0 Edition) Colorectal Cancer | 03/17 | 03/17 | | |
NCT02015169: Phase II Study of Neoadjuvant XELOX + Lapatinib in HER2(+) Gastric Cancer Patients With Liver Metastasis |
|
|
| Completed | 2 | 32 | RoW | Lapatinib, Tykerb, GSK | Samsung Medical Center | HER2-positive Gastric Cancer Patients With Liver Metastasis | 07/17 | 11/17 | | |
VISNU-2, NCT01640444 / 2012-000840-90: Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC) |
|
|
| Completed | 2 | 240 | Europe | FOLFIRI + bevacizumab, FOLFIRI + cetuximab | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Roche Pharma AG | Colorectal Cancer Metastatic | 11/18 | 11/18 | | |
NCT00494221: A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX |
|
|
| Completed | 1/2 | 172 | Japan | AZD2171, cediranib, RECENTIN™, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin), Eloxatin®, 5-FU, Leucovorin, Placebo Cediranib | AstraZeneca | Metastatic Colorectal Cancer | 10/09 | 08/12 | | |
|
NCT00228189: Carcinoembryonic Antigen-loaded Dendritic Cells in Advanced Colorectal Cancer Patients |
|
|
| Completed | 1/2 | 30 | Europe | CEA-loaded dendritic cell vaccine | Radboud University Medical Center | Colorectal Cancer, Liver Metastases | 11/10 | 11/10 | | |
NCT02048540: Neoadjuvant Bev Plus DOF vs DOF in LAGC and Its Association With Circulating Tumor Cell |
|
|
| Completed | 1/2 | 86 | RoW | Bevacizumab, docetaxel oxaliplatin 5-FU CF, Gastrectomy | Chinese PLA General Hospital | Locally Advanced Gastric Carcinoma | 12/13 | 12/13 | | |
NCT01632306: A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer |
|
|
| Terminated | 1/2 | 13 | US | LY2090314, FOLFOX, FOLFOX (leucovorin + 5-fluorouracil + oxaliplatin), Gemcitabine, Gemzar, LY188011, Nab-paclitaxel | Eli Lilly and Company, Mayo Clinic | Pancreatic Cancer | 06/15 | 06/15 | | |
ACTION, NCT02273713: The Addition of Nab-paclitaxel (Abraxane) to First Line Treatment of Metastasized Oesophagogastric Carcinoma |
|
|
| Completed | 1/2 | 154 | Europe | Nab-paclitaxel, Abraxane | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Celgene Corporation | Esophageal Cancer, Toxicity | 03/17 | 03/17 | | |
NCT01206530: FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer |
|
|
| Completed | 1/2 | 50 | US | Hydroxychloroquine, Oxaliplatin, Leucovorin, 5-fluorouracil, Bevacizumab | Abramson Cancer Center of the University of Pennsylvania | Rectal Cancer, Colon Cancer, Metastasis, Adenocarcinoma | 09/17 | 09/17 | | |
